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sarcoma with CD10 expression a distinct entity? A
rare case report with immunohistochemical and
ultrastructural study
Guang-Zhi Yang1*, Jing Li1, Hua Jin2 and Hua-Ye Ding1Abstract: Mammary sarcoma is extremely rare and the diagnosis is established only after metaplastic carcinomas
and malignant phyllodes tumours are excluded. A rare case of not otherwise specified-type sarcoma with CD10
expression in the left breast in a 45-year-old female was presented. It was a high-grade tumour composed of
spindle cells histologically. The immunohistochemical results showed that CD10, vimentin and EGFR were positive
diffusely and SMA presented focally, whereas epithelial markers and other myoepithelial or myogenic markers were
all negative. The electron microscope investigation demonstrated fibroblast-like features. The exact entity of the
tumour remains to be studied because it resembles undifferentiated sarcoma or sarcomatoid metaplastic carcinoma
to some degree, as well as high-grade malignant phyllodes tumour in particular.
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Mammary sarcomas are very rare and most display spe-
cified entities just like liposarcomas or angiosarcomas.
There are still a few cases in the absence of specific dif-
ferentiation, which were diagnosed of pleomorphic sar-
coma or malignant fibrous histiocytoma and so on [1].
Leibl and Moinfar reported seven cases of not otherwise
specified-type sarcoma with the most significant feature
of consistent CD10 expression, which were designated
as NOS-Type sarcoma with CD10 expression (NSCD10)
and were considered as a variant of sarcomas with
myoepithelial differentiation [2]. We also experienced
one case of such sarcoma with diffuse and strong ex-
pression of CD10. Herein, we present the data of hist-
ology, immunophenotype and ultrastructure of the case
and discuss in detail.* Correspondence: guangzhiyang@gmail.com
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A 45-year-old female presented with a giant mass in the
left breast. The lump was first noticed by the patient
herself six years ago. The tumour was only about 1cm in
diameter at that time and grew slowly, thus no treat-
ments were adopted. The tumour grew rapidly in the
past half a year and its diameter reached 10 cm or so,
therefore, the modified mastectomy and axillary lympha-
denectomy were performed in our hospital.
The tumour appeared a circumscribed neoplasm with-
out envelopes, measuring 12 cm × 12 cm × 8 cm. The
cut surface was solid gray in fish appearance with haem-
orrhage and necrosis in the central area (Figure 1).
Under microscopic inspection, the tumour was found to
be mainly composed of spindle cells interspersed with
varying collagen bundles. The spindle cells were
arranged in fascicles, occasionally in storiform pattern
(Figure 2A). The collagen in most areas was scarce and
inconspicuous (Figure 2B), whereas in some focal
regions was rather ample (Figure 2C). Cytological obser-
vation showed that the cells displayed eosinophilic or
amphophilic cytoplasm with ill-defined boundary. Thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The cut surface was solid gray in fish appearance with
haemorrhage and necrosis in the central area.
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chromatin or obvious nucleoli (Figure 2D). Mitoses were
frequent and scored of 15–30 per 10 high power fields and
atypical mitoses were easily found. The tumour invaded the
around breast tissue. After sectioned widely, only one elon-
gated and narrow gland was found (Figure 2A). None of
the axillary lymph nodes was metastasized (0/18).Figure 2 A. The tumour was mainly composed of abundant spindle c
narrow gland was displayed here after widely sectioned. (HE × 50) B. The tu
relatively rare. (HE × 100) C. Collagen bundles among the tumour cells wer
eosinophilic or amphophilic cytoplasm, and striking and vesicular nuclei wi
(HE × 400) E. CD10 was strongly and diffusely positive. (MaxVision method
(MaxVision method × 200).The immunostaining investigation showed that CD10
(56C6, Novacastra) and vimentin (V9, Invitrogen) were
positive strongly and diffusely (more than 90% of tumour
cells) (Figure 2E). Epithelial markers, such as panCK (AE1/
AE3, Invitrogen), CK8/18 (NCL-5D3, Santa Cruz), CK7
(OV-TL 12/30, Dako), EMA (E29, Dako), and basal cell-
type CKs including CK5/6 (D5/16B4, Invitrogen), CK14
(LL001, Santa Cruz), CK17 (E3, Dako) and high molecular
weight CK (34βE12, Novacastra), were all negative. SMA
(1A4, Santa Cruz) was focally positive (about 10%), and
other myoepithelial or myogenic markers, including P63
(4A4, Santa Cruz), Calponin (CLAP, Novacastra), S-100
(S1-61, Santa Cruz), desmin (D33, Dako) and h-caldesmon
(h-CALD, Santa Cruz), were negative. The tumour was also
negative for CD34 (BI-3C5, Invitrogen), CD117 (1DC3,
Invitrogen) and steroid receptors including ER (1D5, Invi-
trogen), PR (1A6, Invitrogen) and AR (H7507, Invitrogen).
EGFR (H11, Dako) was membrane positive strongly and
diffusely (more than 90%) (Figure 2F). Ki-67 (MIB-1, Dako)
index was more than 70%.
Under perspective electron microscope observation,
the tumour cell was spindle, arranged loosely, and no
connection between cells was found. Apparatuses in
cytoplasm were scarce and lysosomes were relatively
abundant. The nucleus was striking with irregular and
distorted envelope and one significant nucleolus (Figure 3).ells. The tumour was absent of glands except that one elongated and
mour cells were gathered and abundant, whereas collagen was
e rather ample. (HE × 100) D. The tumour cells displayed inconspicuous
th coarse chromatin or obvious nucleoli. Mitoses were easily found.
×200) F. EGFR was strongly and diffusely positive.
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structure.
The patient was alive with follow-up for two years.
Local recurrence was found seven months later and re-
operation was performed.
Discussion
In definition, mammary sarcomas are a heterogeneous
group of malignant neoplasms that arise from the mam-
mary stroma [1]. Excluded from this presentation are ma-
lignant lymphoid and hematopoietic tumours such as
non-Hodgkin’s lymphomas, myelomas and granulocytic
sarcomas, which have been rarely reported in the litera-
ture [3,4]. Sarcomas are extremely rare in the breast be-
cause most of previously diagnosed sarcomas, including
some with obvious differentiation such as osteosarcoma or
chondrosarcoma, were later proven to be sarcomatoid
metaplastic carcinomas (MCs) due to modern immuno-
histochemical applications [1]. Therefore, the diagnosis of
MCs must be excluded first by performing immunohisto-
chemistry with adequate epithelial markers for suspected
sarcomas in the breast pathology, as examined in our case
with pan-CK, CK7, CK8/18 and basal-cell type CKs.
Among mammary sarcomas, a few do lack specific dif-
ferentiation as reported by Leibl and Moinfar [2]. In
histopathology, these tumours were composed of spindle
cells with varying collagen fibrous matrix in most cases
or myxoid matrix in a few. The spindle cells displayed
highly polymorphic nuclei with numerous and frequent
atypical mitoses, which confirmed the diagnosis of high-
grade tumours. In immunohistochemistry, the tumours
expressed CD10 consistently and therefore were denom-Figure 3 The tumour cell was spindle and had the striking
nucleus with irregular and distorted envelope and one
significant nucleolus. Apparatuses in cytoplasm were rare and
lysosomes were relatively abundant.inated as NSCD10. NSCD10s were considered as a vari-
ant of sarcomas with myoepithelial features as indicated
as expression of other myoepithelial markers including
SMA, P63, CD29 and Calponin to a variable degree [2].
According to the criteria of histology and immunophe-
notype, our case was also supposed to be diagnosed of
NSCD10.
The perspective electron microscope observation was
also performed in our case. In agreement with the negativ-
ity of all epithelial markers, no evidence of epithelial
differentiation was found. However, though CD10 was
strongly and extensively positive, no evidence of myogenic
differentiation was found either. These results also support
the opinion that none of available so-called myoepithelial
markers is specific for myoepithelial cells until now. It is a
pity that electron microscope investigations had not been
included in the report of Leibl and Moinfar [2]. Since myo-
fibroblastic features are generally more easily documented
by electron microscope rather than immunohistochemistry
in poorly differentiated sarcomas, our case seemed more to
fit into an undifferentiated sarcoma. Thus, it put forward a
question whether NSCD10s were actually one type of un-
differentiated sarcomas.
In the process of diagnosis, malignant phyllodes tumour
(PT) had ever been taken into account since the tumour
demonstrated atypical leaf-like feature locally. While PTs
usually display leaf-like biphasic structure, some cases
with obvious stromal overgrowth may lack it, especially
high-grade or recurrent PTs. In addition, the feature of the
patient’s history, which suggested a probably benign or
borderline lesion at first and then sarcomatous over-
growth, is one of common phenomena in malignant PTs.
In this situation CD34 is a valuable marker as PTs are fre-
quently positive for CD34 [5,6]. The negativity of CD34 in
this case was one of the strong evidences against diagnosis
of malignant PTs.
Stable expression of CD10 is one of the most striking
features of NSCD10s. CD10, also called common acute
lymphoblastic leukemia antigen (CALLA), initially
recognised to be expressed by lymphoid precursor cells
and some B cells, and mainly applied in diagnosis of
haematological malignancies. CD10 is also now used for
diagnosis of various non-haematological neoplasms,
such as endometrial stromal tumours, renal cell carcin-
omas. In breast, CD10 is often adopted as a marker for
myoepithelial cells in differential diagnosis [7]. Recently,
the role of CD10 has been noticed in diagnosis and
prognosis of PTs. A progressive and significant increase
of stromal cell CD10 expression in mammary fibroe-
pithelial lesions with the ability to metastasis had been
reported by two groups respectively [8,9]. Among all
types of fibroepithelial lesions, expression of CD10 was
the greatest in malignant PTs, in which the positive cells
ratios were about 20% and staining intensity was
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was much more extensive and intensive than those of
malignant PTs, which was another proof against diag-
nosing PTs. Given that CD10 is a cell surface neutral
endopeptidase, one member of metalloprotease family, its
role of facilitating malignant potential would be explained
[8], which was also supported in the breast and colorectal
carcinoma [10,11]. It is reasonably inferred that NSCD10s
may rank the top of PTs if they were seen as a continuous
spectrum since an increasing trend in CD10 expression
with malignancy grade in fibroepithelial neoplasms.
The further differential diagnosis comprised of
leiomyosarcoma and myoepithelial carcinoma (MEC) be-
cause of similarity in morphology or immunophenotype.
Leiomyosarcomas may exhibit some morphological fea-
tures associated with NSCD10s, for example, spindle
cells with elongated nuclei with blunt ends. However,
leiomyosarcomas usually do not, or only focally express
CD10. And desmin or h-caldesmon are very useful mar-
kers for differential diagnosis, which are positive in leio-
myosarcomas and negative in NSCD10s. MECs entirely
composed of spindle cells have been reported, which
would cause differential diagnostic problems because
CD10 is diffusely positive too [12]. But MECs also ex-
press other myoepithelial markers extensively, such as
p63, Calponin and SMA and should express CK5/6 or
CK5 which are not expressed by NSCD10s.
Frequent expression of EGFR (epidermal growth factor
receptor, also named as Her-1) is another feature of
NSCD10s. EGFR is a valuable marker in combination with
ER, PR, Her-2 and CK5/6 to identify basal-like breast car-
cinomas in genetic and molecular classification, which
most MCs belong to [13-15]. The expressions of EGFR
and myoepithelial markers in NSCD10s are quite similar
to those in sarcomatoid MCs, suggesting an intrinsic link
between them [16]. With the immunophenotype from car-
cinomatous type to sarcomatous type according to de-
crease of CKs expression, the biological behaviour of MCs
has a tendency from carcinoma to sarcoma too. It is
assumed that NSCD10s represent the extreme sarcoma-
tous end of MCs with myoepithelial differentiation scale.
Recent studies also proposed that CD10 was one of useful
markers to track stem cells in the breast carcinoma,
especially precursors to MCs [17,18]. In the opinion that
the tumour arises from stem cell, MCs are supposed of bi-
directional differentiation to epithelium and myoepithe-
lium, and NSCD10s are rather bi-directional differentiation
to mesenchyma and myoepithelium.
High EGFR expression in NSCD10s also meets a po-
tential for molecular target therapy, which has been veri-
fied in some solid tumours, such as colorectal cancer,
non-small-cell lung cancer and squamous cell carcinoma
of the head and neck [19-21]. However, maybe just as in
breast cancer, EGFR mutation or amplification were rareevents and membranous staining pattern of EGFR might
be the best way to decide eligibility for anti-EGFR ther-
apy, target therapy was valuable in NSCD10s [22]. It is
interesting to know if gene mutation or amplification of
EGFR would be detected in this case.
The origin of NSCD10s still remains to be known.
Mammary sarcomas are traditionally thought to arise
from interlobular mesenchymal elements, which com-
prise the supporting mammary stroma. For example,
angiosarcoma, one of the most common forms of mam-
mary sarcoma, is thought of endovascular origin [23,24].
However, as far as mammary sarcoma with bone and
cartilage is concerned, it is difficult to explain because of
absence of the counterpart. It is even a big challenge to
infer the origin of sarcomas comprising two or more un-
related differentiated tissue elements, such as malignant
mesenchymal tumour reported in the bladder [25]. Now
it is believed that sarcoma originates from primitive cell
with the capacity for totipotent differentiation. So it is
proposed that NSCD10 arises from the stem cell and is
differentiated to myoepithelial cell to some degree, but
the histogenesis remains uncertain. Further studies deal-
ing with molecular features of NSCD10 are valuable to
help elucidate the origin of NSCD10 together with MC
and PT because of their close relations.Conclusion
In summary, we reported a rare case of NSCD10 that is
characterized of extensive and intensive expression of
CD10 in the breast. In our opinion, whether the entity
of the high-grade tumour is distinct remains unclear be-
cause of resemblance to undifferentiated sarcoma or sar-
comatoid MC to some degree, as well as top-grade
malignant PTs in particular. Further studies should be
performed to elucidate the exact entity of NSCD10, es-
pecially dealing with the molecular properties, which will
also deepen knowledge of the relevant tumours.Consent
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